Lung cancer is a heterogeneous and complex disease. Predictive preclinical models are required to advance novel treatments and provide better combination strategies. Our tumor homografts are transplants of GEMM lung tumors into syngeneic hosts, providing robust models with relevant molecular pathology and rich TME.